Hanmi Pharmaceutical Begins Phase 2 Dosing of Belvarafenib in NRAS-Mutated Melanoma
Hanmi Pharmaceutical has initiated phase 2 patient dosing of belvarafenib for NRAS-mutated melanoma in Korea, enrolling the first patient at a university hospital. The multicenter trial will evaluate combination therapy in 45 patients with locally advanced or metastatic disease.
Hanmi Pharmaceutical has initiated patient dosing in a phase 2 clinical trial of belvarafenib in Korea, enrolling the first patient and administering the initial dose at a university hospital. The study is evaluating belvarafenib in patients with locally advanced or metastatic melanoma harboring NRAS gene mutations, a subtype derived from glioma-related tumors.
The first patient dosing was completed slightly more than one month after receiving approval for the phase 2 Investigational New Drug (IND) application from the Ministry of Food and Drug Safety (MFDS) in January.
This phase 2 study is designed as a multicenter, single-arm clinical trial enrolling 45 patients to assess the efficacy and safety of combination therapy with belvarafenib, a targeted anticancer drug candidate, and cobimetinib, a MEK inhibitor.
NRAS-mutated melanoma is associated with a poor prognosis and represents a significant unmet medical need, as no standard therapies have been formally approved domestically or internationally. Currently, belvarafenib is being provided to a limited number of patients under a 'therapeutic use approval' program or as an off-label treatment.
Belvarafenib is an oral targeted anticancer agent designed to inhibit mutations in the RAF and RAS genes, two key components of the mitogen-activated protein kinase (MAPK) signaling pathways involved in tumor cell growth and proliferation. The drug targets tumors harboring BRAF Class II/III mutations and RAS mutations through a differentiated mechanism of action that selectively inhibits RAF dimers.
Unlike conventional BRAF inhibitors, which primarily act on monomeric forms, belvarafenib was designed to concurrently inhibit both BRAF and CRAF dimers, thereby addressing resistance mechanisms associated with RAF dimerization. The combination therapy of belvarafenib and cobimetinib is being evaluated as a treatment strategy designed to overcome the mechanistic limitations of existing BRAF monoclonal antibody and MEK inhibitor combination regimens, with the potential to provide clinical benefits across a broader population of patients harboring genetic mutations.
Melanoma is a refractory malignancy characterized by limited treatment options and a high risk of recurrence. At present, the majority of available treatments are supplied by multinational pharmaceutical companies.